NEW YORK (GenomeWeb News) – Bio-Rad Laboratories said today that it intends to transfer its stock from the American Stock Exchange to the New York Stock Exchange on or around Oct. 24.

 

The firm’s Class A common stock will continue to trade under the ticker BIO, and its Class B common stock will continue to trade under the ticker BIOb.

 

Bio-Rad President and CEO Norman Schwartz said in a statement that the firm’s shareholders “will benefit from the NYSE’s brand, reputation, and trading efficiencies.”